TrialAnnals of the rheumatic diseases2022

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.